GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

manfidokimab   Click here for help

GtoPdb Ligand ID: 13888

Synonyms: AK-120 | AK120
Compound class: Antibody
Comment: Manfidokimab (AK120) is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha (IL-4Rα) subunit that is a component of the IL-4 and IL-13 receptor complexes. It was designed to disrupt signaling mediated by IL-4 and IL-13, in particular to block the pathological T helper 2 (Th2)-mediated inflammatory responses initiated by these cytokines. Peptide sequences for the heavy and light chain domains of manfidokimab match those that form humanized antibody 13E5 H2L2 as claimed in Akeso Pharmaceuticals' patent US20230295312A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Li B, Xia Y, Wang Z, Zhang P. (2023)
Antibody against human il-4ra and use thereof.
Patent number: US20230295312A1. Assignee: Akeso Pharmaceuticals Inc. Priority date: 27/12/2019. Publication date: 21/09/2023.
2. Wynne CJ, Cole A, Lemech C, Wang G, Zhang Y, Chen B, Wang M, Li B, Xia M, Sinclair R. (2023)
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
Dermatol Ther (Heidelb), 13 (10): 2357-2373. [PMID:37668898]